Asset

Meloxicam

Alkermes plc Ordinary Shares

Revenue

No revenue reported in loaded filings.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01436032phase3terminated2011-10-012012-03-01Alkermes, Inc.Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
NCT00945763phase2completed2009-07-012009-11-01Alkermes, Inc.Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery
NCT01084161phase2completed2010-03-012011-01-01Alkermes, Inc.Study to Evaluate the Efficacy, Safety and Tolerability of N1539

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)